Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Major biomarker candidates for Alzheimer’s disease explored: holds promise for improving the diagnosis and ...

08.03.2006


... Management of Dementia



Alzheimer’s disease--specific biomarkers clearly are needed for the differential diagnosis of cognitive impairment in the elderly. What sets age-related disorders like hypertension, hypercholesterolemia and diabetes mellitus apart from Alzheimer’s disease is that each has biomarkers that can be followed easily and repeatedly, not simply to diagnose, but also to monitor response and optimize treatment. In contrast, the current role of clinical laboratory evaluation for dementia is exclusionary. The development of such biomarkers is critical to translating efficiently the new therapeutic approaches for AD under development by many research groups into treatments for the millions who suffer from AD.

The March issue of the Journal of Alzheimer’s Disease (www.j-alz.com) published by IOS Press is devoted to the current research into "Biomarkers for Alzheimer’s Disease.” In the foreword by Elaine R. Peskind and guest editor Thomas J. Montine (University of Washington), the challenges and limitations of our current knowledge of AD biomarkers are outlined. These investigators emphasize that "Progress toward controlling if not eradicating AD is at a crossroads where clinical, pathological and basic science studies have identified therapeutic targets that are now being tested. Critical to translating this knowledge to improved patient care will be developing panels of biomarkers that complement the clinical exam, cognitive testing, and neuroimaging." In six articles, prominent researchers and clinicians involved in AD studies review the search for potential biomarkers for this debilitating disease.


Jeffrey L. Cummings (University of California at Los Angeles) discusses the use of clinical evaluation as a biomarker for AD, pointing out the need for biomarkers that accurately reflect clinical outcomes.

Following this theme, Douglas Galasko (University of California at San Diego) reviews some of the current candidates for AD biomarkers, such as amyloid-beta, tau, and phospho-tau. Other biomarkers that target inflammatory and oxidative damage processes may have future potential.

In a disease with no known cure and no treatments that can delay onset or prevent progression, prediction of future pathology is particularly important. In “The search for antecedent biomarkers of Alzheimer’s disease,” Anne M. Fagan, Cynthia A. Csernansky, John C. Morris, and David M. Holtzman (Washington University in St. Louis), discuss some of the challenges surrounding the development of biomarkers for “preclinical AD.”

Thomas J. Montine, Joseph F. Quinn, Kathleen S. Montine, Jeffrey A. Kaye, and John C.S. Breitner (University of Washington and Oregon Health & Science University), in “Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer’s disease,” discuss how the monitoring of F2-isoprostanes in cerebro-spinal fluid (CSF) is showing promise as a diagnostic tool for monitoring potential anti-oxidant therapies for AD.

Inflammatory processes have also been implicated in AD. Robert E. Mrak and W. Sue T. Griffin (University of Arkansas) review proinflammatory cytokines as potential markers for AD, pointing out in “Inflammatory biomarkers in Alzheimer’s disease” the difficulties in the use of such markers due to complicating genetic factors.

Finally, Jing Zhang, David R. Goodlett, and Thomas J. Montine (University of Washington) discuss recent advances in genomics, proteomics, and metabolomics. In “Proteomic Biomarker Discovery in Cerebrospinal Fluid for Neurodegenerative Diseases,” the prospect for clinical diagnosis via unique protein markers is reviewed, as well as the practical limitations of proteomic analysis of human CSF.

In addition to the articles, the issue features transcripts of two live panel discussions of the Alzheimer Research Forum, “Imaging in Alzheimer’s Disease: The Current State of Affairs” and “Making a BioMark on Alzheimer Disease.” (The Alzheimer Research Forum, founded in 1996, is the web’s most dynamic scientific community dedicated to understanding Alzheimer’s disease and related disorders.)

Astrid Engelen | alfa
Further information:
http://www.j-alz.com

More articles from Life Sciences:

nachricht Complementing conventional antibiotics
24.05.2018 | Goethe-Universität Frankfurt am Main

nachricht Building a brain, cell by cell: Researchers make a mini neuron network (of two)
23.05.2018 | Institute of Industrial Science, The University of Tokyo

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

When corals eat plastics

24.05.2018 | Ecology, The Environment and Conservation

Surgery involving ultrasound energy found to treat high blood pressure

24.05.2018 | Medical Engineering

First chip-scale broadband optical system that can sense molecules in the mid-IR

24.05.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>